| Market Cap | 2.68M | P/E | - | EPS this Y | -190.90% | Ern Qtrly Grth | - |
| Income | -59.71M | Forward P/E | -0.05 | EPS next Y | 21.30% | 50D Avg Chg | -47.00% |
| Sales | - | PEG | 0.00 | EPS past 5Y | - | 200D Avg Chg | -95.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | 12.70% | 52W High Chg | -99.00% |
| Recommedations | 2.70 | Quick Ratio | 0.77 | Shares Outstanding | 39.33M | 52W Low Chg | 5.00% |
| Insider Own | 4.87% | ROA | -79.64% | Shares Float | 36.94M | Beta | 0.34 |
| Inst Own | 22.81% | ROE | -239.32% | Shares Shorted/Prior | 2.79M/306.94K | Price | 0.06 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 7,783,129 | Target Price | 3.67 |
| Oper. Margin | - | Earnings Date | Mar 22 | Volume | 13,881,465 | Change | -10.36% |
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia. The company also develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis; and CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also initiated an expanded access program to provide Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.
| Maxim Group | Hold | Jul 14, 22 |
| SVB Leerink | Market Perform | Jul 14, 22 |
| Cantor Fitzgerald | Neutral | Jul 14, 22 |
| WBB Securities | Strong Buy | Jun 8, 22 |
| SVB Leerink | Outperform | Feb 16, 22 |
| WBB Securities | Buy | Feb 2, 22 |
| SVB Leerink | Outperform | Sep 9, 21 |
| WBB Securities | Speculative Buy | Mar 31, 21 |
| Cantor Fitzgerald | Overweight | Nov 25, 20 |